Condition: Solid Tumor, Adult · BRCA1 Mutation · BRCA2 Mutation · Sponsor: Acerand Therapeutics (Shanghai) Limited
The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.
This description comes directly from the study's public registry record.
Teresa Shi · 8613916513539 · teresa.shi@acerand.com
Sherwin Cai, MD · sherwin.cai@acerand.com
Always discuss trial participation with your own doctor first.
| Chongqing Cancer Hospital | Chongqing, Chongqing Municipality, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Sun Yat-Sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Anyang Cancer Hospital | Anyang, Henan, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| Hubei Cancer Hospital | Wuhan, Hubei, China | Recruiting |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
| Jinan Central Hospital | Jinan, Shandong, China | Recruiting |
| Qilu Hospital Shangdong University | Jinan, Shandong, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
| Second Hospital Affiliated to Shanxi Medical University | Taiyuan, Shanxi, China | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06380660